Manjiri Bakre built OncoStem and the CanAssist test so Indian breast-cancer patients are not sent for chemo they do not need

Every year, a great many Indian women with early breast cancer are sent for chemotherapy. For some, it is the thing that saves their life. For others, it is months of poison they never needed, because the tumour was never going to come back and nobody had a reliable way to tell the difference. Manjiri Bakre spent more than two decades as a scientist before she decided to close that gap. The company she built, OncoStem Diagnostics, exists to answer one question with more confidence than a doctor’s best guess: who truly needs the chemo, and who can be spared it.

It is not a consumer app or a flashy brand. It is a hard, slow, deep-science business, the kind that takes years to validate and even longer to earn a clinician’s trust. That Manjiri built it at all, as a solo woman founder in Indian biotech, is notable. That she built it on Indian patients, for a problem the imported tests were quietly getting wrong here, is the part worth understanding.

A scientist’s training

Manjiri is a cell biologist by training, with a PhD from the Indian Institute of Science in Bengaluru. Her research years took her well beyond India. She did postdoctoral work in the United States, at Mount Sinai and at the University of California, San Diego, and later worked at the Genome Institute of Singapore on stem cells. By the time she returned to build a company, she had spent years inside cancer biology and drug discovery across three countries.

Back in India, she held senior research roles before founding anything, including principal scientist at Philips Research in Bangalore and a group leader position at the biotech firm Avesthagen. This is the unglamorous part of a deep-tech founder’s story that often gets skipped. She was not a young disruptor with a clever hunch. She was a specialist who understood the underlying biology cold, which is exactly what a diagnostics company needs at its centre, because the science has to be right before anything else matters.

The friend she could not save

The reason she chose this particular problem goes back to her student days. A close friend was diagnosed with breast cancer while Manjiri was doing her PhD. The friend was young, around thirty, and she went through treatment, chemotherapy included. She died within about two years anyway. Accounts of the details vary a little across interviews, but the shape of it does not: Manjiri watched someone she loved go through the full ordeal of treatment and lose regardless.

That loss sat with her for years. What stayed was not only the grief but a scientist’s discomfort with how blunt the whole process was. Cancer treatment, she came to believe, was being delivered as one-size-fits-all, when the biology underneath was anything but uniform. Some patients were being over-treated, some under-treated, and the tools to tell them apart, where they existed at all, had not been built with patients like hers in mind.

The flaw she saw in the imported tests

By the time Manjiri was ready to act, tests that predicted breast-cancer recurrence did exist. They came from the West, cost a few lakh rupees, and had been developed and validated largely on Western patients. Her objection was not that they were bad science. It was that the biology of breast cancer in Indian and other Asian women is not identical to the population those tests were tuned on, and a prognostic tool is only as good as the patients it was calibrated against.

There was also the price. At a few lakh rupees a test, a recurrence assay was out of reach for the overwhelming majority of Indian patients, which meant the decision about chemotherapy kept defaulting to broad clinical rules rather than the specific biology of the woman in the chair. Manjiri set out to build something validated on Indian patients and priced so that an ordinary family could actually use it. She founded OncoStem Diagnostics in Bengaluru in 2011 to do it.

What CanAssist actually does

The product that came out of it, launched in 2016, is called CanAssist Breast. It is a prognostic test for early-stage, hormone-receptor-positive breast cancer. In plain terms, it looks at a patient’s own tumour tissue, measures a panel of protein biomarkers using standard pathology techniques, and combines those readings with clinical factors such as tumour size, grade and whether the lymph nodes are involved. A machine-learning algorithm turns all of that into a single risk score, placing the patient in a low or high risk band for the cancer returning within five years.

The point of that score is a real decision. A woman who comes back clearly low risk may, with her oncologist, reasonably choose to skip chemotherapy and avoid its toll. A high-risk result argues for the more aggressive path. The test does not replace the oncologist; it gives them evidence grounded in the patient’s own biology instead of population averages. That is the whole pitch, and it is a serious one.

None of it would count for anything without validation, which is where most of the company’s early life went. OncoStem approached scores of hospitals and ultimately worked with a dozen of them, among them Manipal, the Rajiv Gandhi Cancer Institute, Jaslok and Apollo, to assemble tumour samples and years of follow-up data on thousands of Indian breast-cancer patients. The test and its validation have been published in the peer-reviewed oncology literature. In a field where it is easy to make a confident claim and hard to prove one, that evidence is the real moat.

The money, and the believers

A diagnostics company burns years and cash before it earns a rupee of meaningful revenue, so who backs it early tells you a lot. OncoStem raised venture funding from Sequoia Capital India and Artiman Ventures, and reported totals have sat in the range of roughly seven to nine million dollars across its rounds. The figures vary between trackers, so treat the exact number as approximate rather than official.

One early believer stands out. Kiran Mazumdar-Shaw, the founder of Biocon and one of the most important figures in Indian biotech, backed Manjiri’s work in its early days. For a first-time founder building something this technical, the endorsement of someone who had built India’s biggest biopharma company from scratch was its own kind of capital. It signalled that a serious scientist-entrepreneur took the science seriously.

Reach, price and recognition

CanAssist Breast is priced at roughly 65,000 rupees, which the company puts at a fraction of what the imported recurrence tests cost. That gap is the point. A test that sits at a few lakh rupees is a test most Indian families will never order; one at a fraction of that price can actually change what happens in the clinic. Affordability, here, is not a marketing line. It is the difference between a tool that exists and a tool that gets used.

The work has drawn recognition along the way. Manjiri was named Health Tech Innovator of the Year at an industry awards in 2020, and OncoStem has picked up honours including a CII Startupreneur award in biotech and pharma and an Aegis Graham Bell award in diagnostics. Awards are not outcomes, and the real measure is patients tested and chemotherapy courses safely avoided. But for a deep-tech company grinding through the long validation years, the recognition helped keep the lights, and the morale, on.

Manjiri Bakre’s net worth, honestly

Her name will pull up net-worth figures. They are not reliable. OncoStem is a privately held, venture-backed company, its ownership is split among the founder, institutional investors and others, and none of that is disclosed in a way that lets anyone compute a genuine personal figure. Any specific number you see attached to her is a guess, and we would rather say so than repeat it.

What can be stated responsibly is the shape of it. Manjiri is the founder and chief executive of a company that has raised several million dollars and holds valuable, patented diagnostic technology. On paper, a founder’s stake in a company like that can be worth a great deal, but it is illiquid and entirely contingent on how OncoStem does over time. The honest answer to the net-worth question is that there is no credible public figure, and that for a founder whose life’s work is measured in women spared unnecessary chemotherapy, it is also close to the least interesting thing about her.

What Manjiri Bakre’s story teaches Indian founders

The first lesson is that domain depth is not a liability to rush past. Manjiri spent more than twenty years becoming a genuine expert before she built OncoStem, and that expertise is the company. In a startup culture that prizes speed and youth, hers is a reminder that some problems can only be solved by someone who has earned the right to understand them, and that arriving late, with real knowledge, is its own advantage.

The second is about building for your own context rather than importing someone else’s. The imported tests were not wrong so much as not ours. Manjiri’s insight was that validating on Indian patients, and pricing for Indian families, was not a compromise on a global product but the entire opportunity. A lot of the most useful Indian companies will be built exactly there, in the gap between what works for the West and what actually works here.

The third is patience, which deep tech demands and the funding cycle rarely rewards. A diagnostics company cannot be hacked to growth in eighteen months; it needs years of samples, follow-up and peer review before anyone should trust it, and Manjiri chose that slow path on purpose. Founders chasing the next fast category could do worse than study a woman who picked a hard problem, went deep, and stayed.

Frequently asked questions about Manjiri Bakre and OncoStem

Who is Manjiri Bakre?

Dr Manjiri Bakre is the founder and CEO of OncoStem Diagnostics, a Bengaluru cancer-diagnostics company she started in 2011. A cell biologist with a PhD from the Indian Institute of Science and postdoctoral research in the US and Singapore, she built OncoStem’s CanAssist Breast test to help early breast-cancer patients in India avoid unnecessary chemotherapy.

What is CanAssist Breast?

CanAssist Breast is a prognostic test for early-stage, hormone-receptor-positive breast cancer. It measures a panel of protein biomarkers in a patient’s tumour tissue, combines them with clinical factors, and uses a machine-learning algorithm to produce a recurrence-risk score. A low-risk result can support a decision, made with the oncologist, to safely skip chemotherapy.

Why build a test on Indian patients?

Existing recurrence tests were developed and validated largely on Western patients and cost a few lakh rupees. Manjiri Bakre argued that the biology of breast cancer in Asian women differs, so a test should be validated on Indian patients, and that it had to be affordable to actually be used. OncoStem validated CanAssist Breast with about a dozen Indian hospitals on thousands of local patients.

Who funded OncoStem Diagnostics?

OncoStem raised venture funding from Sequoia Capital India and Artiman Ventures, with reported totals in the range of roughly $7–9 million across rounds (figures vary by source). Biocon founder Kiran Mazumdar-Shaw was an early supporter of Manjiri Bakre’s work.

What is Manjiri Bakre’s net worth?

There is no verified public net-worth figure. OncoStem is a privately held, venture-backed company with undisclosed ownership, so any specific number online is an estimate. She is the founder and CEO of a company holding patented diagnostic technology, which makes her stake valuable on paper but illiquid and impossible to price precisely.

What can founders learn from her story?

Three things: domain depth matters (she spent 20+ years as a scientist before founding OncoStem), build for your own context rather than importing a Western product, and deep tech rewards patience, since a diagnostics company needs years of validation and peer review before anyone should trust it.